Serum half-life and tumor localization of a chimeric antibody deleted of the CH2 domain and directed against the disialoganglioside GD2.
Authors:
Open Access
- 1 August 1990
- journal article
- research article
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 87 (15) , 5702-5705
Abstract
Recombinant techniques allow one to engineer an antibody molecule and, in this way, manipulate its properties and functions. We engineered a chimeric human/mouse antibody to the tumor-associated antigen ganglioside GD2, with the aim of decreasing its serum half-life, maintaining its full antigen-binding capacity, and deleting its effector functions, thus making it a potentially useful reagent for the radioimaging of tumors. To this end, the constant region of the human gamma 1 chain was mutated by deleting the second domain (CH2). Here we show that the CH2-deleted antibody (ch14.18-delta CH2) was cleared from the blood of athymic (nu/nu) mice bearing human melanoma tumors with the same kinetics as human IgG F(ab')2. At a beta t1/2 of 12 hr, 0.9% of the injected dose of 125I-labeled ch14.18-delta CH2 was found per milliliter of blood 24 hr after i.v. injection. In biodistribution experiments, 125I-labeled ch14.18-delta CH2 targeted specifically to melanoma xenografts, achieving optimal tumor-to-tissue ratios 12-16 hr after i.v. injection. ch14.18-delta CH2 was localized to the melanoma tumors more rapidly and with better localization ratios than the intact chimeric antibody ch14.18. Sixteen hours after i.v. injection, the tumor-to-blood and tumor-to-liver ratios of ch14.18-delta CH2 were 5 and 12, respectively, while optimal localization ratios obtained for ch14.18 were 1 and 5, respectively, but 96 hr after injection. A reagent such as ch14.18-delta CH2 should be useful for radioimmunodetection of human tumors because of reduced immunogenicity, increased targeting specificity, and rapid clearance from circulation.Keywords
This publication has 26 references indexed in Scilit:
- High-level expression of chimeric antibodies using adapted cDNA variable region cassettesJournal of Immunological Methods, 1989
- Labeling monoclonal antibodies and F(ab')2 fragments with the alpha-particle-emitting nuclide astatine-211: preservation of immunoreactivity and in vivo localizing capacity.Proceedings of the National Academy of Sciences, 1989
- Mouse/human chimeric monoclonal antibody in man: kinetics and immune response.Proceedings of the National Academy of Sciences, 1989
- Improved procedure for preparation of F(ab′)2 fragments of mouse IgGs by papain digestionJournal of Immunological Methods, 1989
- Specific and stable labeling of antibodies with technetium-99m with a diamide dithiolate chelating agent.Proceedings of the National Academy of Sciences, 1988
- Generation of an antibody with enhanced affinity and specificity for its antigen by protein engineeringNature, 1987
- Current status of cancer imaging with radiolabeled antibodiesJournal of Cancer Research and Clinical Oncology, 1987
- Comparative tumour localization of antibody fragments and intact IgG in nude mice bearing a CEA-producing human colon tumour xenograftEuropean Journal of Cancer and Clinical Oncology, 1985
- Transfectomas Provide Novel Chimeric AntibodiesScience, 1985
- Preparation of F(ab′)2 fragments from mouse IgG of various subclassesJournal of Immunological Methods, 1983